Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): 4D-110

            Therapeutic Area: Ophthalmology Product Name: 4D-110

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: 4D Molecular Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination June 24, 2021

            Details:

            Roche requested that 4DMT conclude the Roche-funded 4D-110 trial in advanced choroideremia patients as a result of Roche’s assessment of a change in the risk-benefit profile.